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3ABSTRACT
Enteroviruses (EVs), such as the Coxsackie B-viruses (CVBs), are common human 
pathogens, which can cause severe disease including meningitis, myocarditis and 
neonatal sepsis. EVs encode two proteases (2Apro and 3Cpro), which perform the 
proteolytic cleavage of the CVB polyprotein and also cleave host cell proteins to 
facilitate viral replication. The 2Apro cause direct damage to the infected heart and tools 
to investigate 2Apro and 3Cpro expression may contribute new knowledge on virus-
induced pathologies. Here, we developed new antibodies to CVB-encoded 2Apro and 
3Cpro; Two monoclonal 2Apro antibodies and one 3Cpro antibody were produced. Using 
cells infected with selected viruses belonging to the EV A, B and C species and 
immunocytochemistry, we demonstrate that the 3Cpro antibody detects all of the EV 
species B (EV-B) viruses tested and that the 2Apro antibody detects all EV-B viruses 
apart from Echovirus 9. We furthermore show that the new antibodies work in Western 
blotting, immunocyto- and immunohistochemistry, and flow cytometry to detect CVBs. 
Confocal microscopy demonstrated the expression kinetics and revealed a preferential 
cytosolic localization of the proteases in CVB3 infected cells. In summary, the new 
antibodies detect proteases that belong to EV species B in cells and tissue using multiple 
applications. 
Key Words: Enterovirus; Coxsackievirus; Protease 2A; Protease 3C; Monoclonal 
antibodies
Abbreviations: 2Apro, Enteroviral protease 2A; 3Cpro, Enteroviral protease 3C; EV, 
Enterovirus; CVA Coxsackievirus A; CVB Coxsackievirus B; RT-PCR, Real Time 
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51. INTRODUCTION
Enteroviruses (EVs) are important human pathogens and they are the most common 
infectious viruses in humans, particularly in young children. EVs and especially the 
Coxsackievirus B (CVB) group have been associated with many diseases. These 
include acute illnesses such as severe infections in neonates, sepsis, meningitis, 
myocarditis, human foot-and-mouth disease and pancreatitis (Calderón et al., 2016; 
Gaaloul et al., 2014; Orbach et al., 2016; Persichino et al., 2016). In addition, EVs have 
been connected to chronic diseases such as type 1 diabetes and dilated cardiomyopathy 
(Gaaloul et al., 2014; Laitinen et al., 2014; N’Guyen et al., 2016; Oikarinen et al., 2014; 
Yeung et al., 2011). 
The EV genome consists of a single positive stranded RNA molecule, with one open 
reading frame encoding the viral polyprotein. This polyprotein contains two viral 
proteases, 2Apro and 3Cpro, which perform the proteolytic cleavage of the polyprotein 
into the structural capsid proteins VP1-4 and nonstructural proteins required for virus 
replication. Further to this, the proteases also cleave host cell proteins in order to 
facilitate the propagation of the virus and to evade host cellular immune responses 
(Feng et al., 2014; Laitinen et al., 2016; Lamphear et al., 1993; Lei et al., 2013; Lind et 
al., 2016, 2014, 2013; Mukherjee et al., 2011; Weidman et al., 2001), which may also 
contribute to pathology. Indeed, the cleavage of cardiac specific proteins by the viral 
protease 2Apro has been shown to contribute to CVB-induced myocarditis (Badorff et 
al., 2000; Barnabei et al., 2015; Lim et al., 2013; Luo et al., 2010; Massilamany et al., 
2014; Wong et al., 2012). Given that the predicted substrate sequences for the proteases 
are present in numerous host proteins (Laitinen et al., 2016), it is likely that cleavage 
6of other human host proteins contributes to the damage in other organs during CVB 
infection. 
To better understand the associations between EVs and various diseases and the 
potential mechanisms through which these viruses cause pathology, appropriate 
molecular tools are essential. Currently, available methods for detecting EVs in both 
clinical and research laboratories are mainly founded on nucleic acid recognition based 
methodologies (RT-PCR, hybridization and next generation sequencing) (Ettischer-
Schmid et al., 2016; Kramná et al., 2015; Laiho et al., 2016; Maccari et al., 2016; 
Yousef et al., 1987), but antigen based immunoassays (Li et al., 2011; Zhang et al., 
2016) have also been developed to detect virus-specific antibodies in serum samples. 
Moreover, mass spectrometry has been utilized to directly detect viral proteins in 
experimental and patient samples (Calderaro et al., 2014; Laiho et al., 2016). In clinical 
laboratories current trends focus predominantly on PCR-based techniques (Luoto et al., 
2016), whereas antibody based approaches are widely used in academic research. 
One of the most frequently used antibodies in EV detection is the monoclonal antibody 
clone 5-D8/1 (Maccari et al., 2016; Yousef et al., 1987), which recognizes an N-
terminal epitope of the VP1 capsid protein (Samuelson et al., 1995) in a large spectrum 
of EV species A and B serotypes (Laiho et al., 2015; Miao et al., 2009). Currently, 
antibodies specifically targeting CVB encoded proteases are rare and to our knowledge, 
none are commercially available highlighting the need for their development.
In the present study we introduce novel monoclonal rat antibodies raised against the 
CVB proteases 2Apro and 3Cpro, and describe several applications by which they 
successfully detect EVs, including Western blotting, immunocyto- and 
7immunohistochemistry and flow cytometry. Using these reagents we also provide 
additional insight into the kinetics of protease expression and cellular localization during 
acute infection in cultured cells. 
82. MATERIALS AND METHODS
2.1. Cloning and production of 2Apro and 3Cpro
CVB3 Nancy (UniProtKB/Swiss-Prot: P03313.4) polyprotein sequence was used as a 
template to construct recombinant His-tagged 2Apro and 3Cpro proteases. Artificial 
genes encoding the proteases were ordered from Life Technologies (Germany) and 
were cloned into the pBVboostFGII expression vector as described in (Heikura et al., 
2012; Laitinen et al., 2005). Proteases were expressed in E. coli, strain BL21-AI (Life 
Technologies), and then purified with immobilized metal affinity chromatography 
(IMAC) using the ÄKTA P-100 liquid chromatography system and HisTrap FF crude 
IMAC columns (GE Healthcare Bio-Science AB). 
2.2. Generation of hybridoma and production of antibodies
Monoclonal antibodies against CVB3 (Nancy) 2Apro and 3Cpro proteases were produced 
through the immunization of Wistar rats with the purified proteases (GenScript, Hong 
Kong). Hybridomas were generated by electrofusion and the positive clones were 
positively selected for the detection of the proteases and negatively selected for their 
recognition of the His-tag by ELISA (Genscript). After initial Western blotting using 
CVB3 infected HeLa cell lysates (see below) and immunohistochemistry (IHC) 
screening using pancreas tissue from CVB infected mice (see below), two 2Apro 
recognizing antibody clones (denoted 2A-1 and 2A-2) and one 3Cpro clone (denoted 
93C) were selected for antibody production and the resulting antibodies were used in the 
present study. 
2.3. Cell lines, viruses and cell microarray
HeLa cells, grown in standard RPMI 1640 medium supplemented with 10% inactivated 
fetal bovine serum (FBS) and 2 mM L-glutamine at 37 ᵒC and 5% CO2, were utilized 
for virus infections (Lind et al., 2016). Cells were passaged the day before infection. 
The generation of the cell microarray encompassing green monkey kidney cells (GMK 
and Vero), carcinomic human alveolar basal epithelial cells (A549), human 
rhabdomyosarcoma muscle cells (RD) and carcinomic human cervix epithelial cells 
(HeLa) infected with a selection of human viruses has been reported (Laiho et al., 
2015). A list of the viruses used in this study, is presented in Supplementary Table 1.
2.4. Western blot
HeLa cells were infected with one of the six CVB serotypes (MOI 20) and the infections 
were terminated at the indicated time points. Mock infected cells served as controls. 
Proteins were isolated, separated by SDS-PAGE and detected using Western blot, as 
described in (Lind et al., 2013). The recombinant proteases were used as positive 
controls. Primary antibodies used were as follows: 2A-1 diluted 1:2000 from a 100 
µg/ml stock and 3C diluted 1:2000 from a 180 µg/ml stock, VP1 (1:500, clone 5-D8/1, 
Dako Cytomation, Denmark) and anti-actin (1:30,000, MP Biomedicals, Aurora, Ohio, 
USA). The secondary antibodies utilized were HRP conjugated goat-anti mouse for the 
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VP1 and actin antibodies (Bio-Rad, 1:1000 dilution) and goat anti-rat for 2A and 3C 
antibodies (Bio-Rad, 1:10,000).
2.5. Intracellular flow cytometry 
HeLa cells were infected for 6h with the indicated CVBs (MOI 20), after which the 
cells were fixed with 1% paraformaldehyde at room temperature. Mock infected cells 
served as controls. Permeabilization and intracellular staining were performed in 
Perm/Wash (BD) using anti-VP1 antibody (clone 5-D8/1, Dako, diluted 1:50) and/or 
the primary rat 2A-2 or 3C antibodies diluted 1:250 or 1:50 from 100 µg/ml stocks 
respectively. The primary antibodies were detected using a goat anti-mouse Alexa Fluor 
647- or Alexa Fluor 488-conjugated secondary antibodies (Invitrogen; VP1), or a
phycoerythrin (PE) labeled goat anti-rat IgG antibody (Invitrogen; 2A-2 and 3C). VP1 
and protease positive cells were detected with a BD AccuriTM C6 and BD Fortessa. 
Samples were analyzed using FlowJo software (Tree Star). 
2.6. Animals
C57BL6 and non-obese diabetic (NOD) mice were bred and housed in a specific-
pathogen-free environment at Karolinska Institutet, Stockholm, Sweden. Animals were 
infected with 103-108 PFU CVB1, -3, -4 or -5 administered in 200 µl RPMI 1640 via 
the intraperitoneal route. Untreated mice, or those mock-infected with RPMI 1640 
alone served as controls. Systemic viral spread was confirmed by viremia 
measurements using plaque assay or RT-PCR on days 3-5 post infection (data not 
shown), as previously described (Larsson et al., 2015). All animal experiments were 
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approved by a local ethics committee and conducted in accordance with the NIH 
principles of laboratory animal care and the Swedish law.
2.7. Immunocyto- and immunohistochemistry
Pancreas tissue, harvested from CVB infected  mice between day 3 and 5 post infection, 
were fixed in 4% formaldehyde in PBS for 24 h. Negative control samples were 
collected from uninfected mice. After dehydration and paraffin embedding, the 
formalin-fixed paraffin embedded (FFPE) tissues were cut in 0.5 µm thick sections and 
heat-fixed to Superfrost® Plus microscope slides (Thermo Scientific, Germany). 
Prior to immunocytochemical (ICC, cell microarray) and IHC (tissue sections) staining, 
antigen retrieval was performed by boiling samples for 2 x 2.5 min in buffer containing 
10 mM citrate pH 6 (2A-2) or 10 mM Tris and 1mM EDTA pH 9 (3C and VP1-bio; see 
below). Comprehensive antibody titrations were performed and optimal dilutions were 
determined to be 1:4000 for the 2A-2 antibody and 1:100 for the 3C antibody (both 
from 100 µg/ml antibody stocks). Detection was performed with a biotinylated goat 
anti-rat IgG antibody (Vector Laboratories, USA). Staining with the secondary 
antibody alone showed no positivity (data not shown). To confirm the presence of virus, 
sequential tissue sections were probed with a biotinylated VP1 antibody (clone 5-D8/1, 
Dako Cytomation, Denmark). As this antibody is of murine origin, it was biotinylated 
(Capra Science, Sweden) before use (hence denoted VP1-bio). The VP1-bio antibody 
was used at a 1:100 dilution (70 µg/ml stock), and due to the biotinylation, no secondary 
antibody was required. Staining in ICC and IHC was visualized using horseradish 




HeLa-cells grown on glass coverslips were infected with CVB3 (Nancy, MOI 20) for 
2, 4 or 6 h. The cells were fixed with 4% PFA and permeabilized with 0.2% Triton-
X100. Cells were stained with either 2A-2 (1:100) or 3C (1:100) followed by an Alexa-
fluor 488-conjugated secondary goat anti-rat IgG antibody (1:200; Thermo Fisher 
Scientific). Nuclear lamina was stained using a polyclonal antibody to Lamin B1 
(ab16048, Abcam, 1:500) and the secondary antibody Alexa-fluor 568-conjugated 
goat anti-rabbit IgG (A11011, Life Technologies, 1:250). Nuclei were visualized with 
DAPI 285 nM (Sigma). Cells were covered with ProLong Diamond antifade reagent 
(Molecular Probes) and the staining was analyzed by confocal microscopy (Nikon 
A1R). Alexa 488 was excited with a 488 nm laser and fluorescence was collected with 
a 500-550 nm band-pass filter. Alexa 568 was excited with a 561 nm laser and the 
fluorescence was collected with a 570-620 nm band-pass filter. DAPI was excited with 
405 nm laser and fluorescence was collected with a 425-475 band-pass filter. The image 
size was adjusted to 1.024 x 1.024 pixels and 0.15 µm thick Z-stack slices were imaged 
with averaging of two images. The pinhole was set to 1.2 Airy unit. 
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3. RESULTS
3.1. Protease antibodies detect CVB1-6 infections by Western blot
Two monoclonal rat antibodies against CVB3 (Nancy) 2Apro (here denoted 2A-1 and 
2A-2) and one antibody against CVB3 (Nancy) 3Cpro were produced, as described in 
materials and methods. Western blot analysis of cell lysates prepared from CVB3 
infected HeLa cells revealed that all three antibodies detected protein bands with the 
expected 2Apro and 3Cpro molecular weights (data not shown). The 2A-1 and 3C 
antibodies were tested for their ability to detect recombinant 2Apro and 3Cpro. 2A-1 
detected 2Apro but not 3Cpro, and the 3C antibody only detected 3Cpro (Figure 1A and 
B). A time course CVB infection study in HeLa cells revealed the appearance of 2Apro
in the cell lysate at 3 h post infection (Figure 1 C). The highest 2Apro level was observed 
around 5 h post infection, after which the expression declined. In comparison, 3Cpro 
was initially detected at four hours post infection and was then present at a fairly 
constant level during the 9 h time course. 
To investigate if the newly developed antibodies detect proteases of heterotypic, but 
closely related EVs, and to compare the antibodies with the commonly used anti-VP1 
antibody clone 5-D8/1, further Western blot analyses were performed. HeLa cells were 
infected with either of the six CVB serotypes and cell lysates were harvested at 6 h post 
infection and analyzed with the different antibodies. The 2A-1 and 3C antibodies 
recognized bands with the expected size of 2Apro and 3Cpro, respectively, in cell lysates 
from all six CVB serotypes (Figure 1 D). The VP1 antibody, as expected, detected all 
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six serotypes however, of note, the recognition of CVB6 was weaker than the other 
serotypes, an observation which we have also previously documented (Saarinen et al., 
2018). Contrastingly, both protease antibodies demonstrated a robust detection of 
CVB6. 
3.2. EV serotype B (EV-B) species are recognized by the protease antibodies in 
immunocytochemistry 
Given the ability of the protease antibodies to recognize viral proteins in lysates from 
CVB infected cells by Western blot, we next set out to determine if the antibodies could 
also detect viral proteins with ICC. To this end, an array of fixed and paraffin embedded 
human cell lines infected with various EVs was used (Table 1 and (Laiho et al., 2015)). 
The array also provides a method to determine the breadth of EVs that the antibodies 
can recognize. The 2A-1 and -2, 3C and VP1 antibodies were used to stain the cell 
array. However, pilot studies suggested that the 2A-1 antibody did not detect virus 
positive cells in formalin fixed tissue (data not shown) and therefore it was not used in 
these studies. 2A-2 detected cells infected with all six different CVB serotypes, 
Echovirus 4, 6, 11, 30 and CVA9, but it did not recognize any EV-A serotypes, 
poliovirus nor the human parechovirus 1 (Table 1). Positivity was also seen with the 
3C antibody in cells infected with all six CVBs, Echovirus 3, 4, 6, 9, 11, 30 and CVA9. 
However, 2A-2 did not detect EV-A serotypes and poliovirus (Table 1). When 
compared to the commonly used VP1 antibody (DAKO, clone 5-D8/1), the 2A-2 and 
3C antibodies demonstrated a higher level of selectivity in their recognition of viruses 
as they only detected EV-B serotypes, whereas the VP1 antibody detected many EV-A 
viruses. Uninfected cells and infected cells incubated with secondary antibody alone 
acted as negative controls and showed no positive staining (data not shown).
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3.3. Protease antibodies detect CVBs in CVB infected mouse pancreas
To fully study the mechanisms behind virus-instigated pathologies, access to a 
comprehensive range of antibodies capable of detecting virus proteins in tissue samples 
from patients and in experimental disease models is highly advantageous. Mouse 
models have been widely utilized to study the pathogenesis of CVB-induced diseases. 
In contrast to many other EVs, CVBs are capable of infecting mice at any age and they 
also have a similar tissue tropism to that seen in humans, including the pancreas and 
heart. As such, mice have therefore become useful models for studies on myocarditis, 
pancreatitis and Type 1 diabetes (reviewed in (Fairweather et al., 2012; Jaïdane et al., 
2009)). 
In order to examine whether the protease antibodies are capable of detecting CVB 
proteases in tissue samples, we utilized pancreas tissue collected at different time points 
post infection from mice infected with CVB3 (homotypic detection) and CVB1, -4 and 
-5 (heterotypic detection). FFPE pancreas sections were stained with 2A-2, 3C or VP1-
bio antibodies. CVBs typically infect the exocrine pancreas tissue in mice (Flodström 
et al., 2002; Jaïdane et al., 2010) and all of the antibodies successfully stained the 
exocrine tissue in CVB infected animals (CVB3 and -5 infected animals, Figure 2; 
CVB1 and -4, data not shown). As expected (Flodström et al., 2002; Jaïdane et al., 
2010), none of the antibodies detected viral proteins in the pancreatic islets of these 
infected mice (Figure 2 and data not shown). Furthermore, there was an absence of non-
specific staining in the pancreas of uninfected control mice (Fig 2 A, C, E and G). 
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3.4. CVB infected cells are detected by flow cytometry using the protease 
antibodies 
In flow cytometry, single cells can be counted and sorted with simultaneous qualitative 
and quantitative analysis of multiple parameters. As such, antibodies targeting proteins 
of interest are important tools in classical flow cytometry-based analyses and can be 
either directly conjugated with a fluorescent label or used in combination with a labeled 
secondary antibody. Flow cytometry has been used in EV research to, for example, 
identify infected cells (Hühn et al., 2007), assess the expression kinetics of VP1, to 
study the efficacy of cytokines in regulating cellular permissiveness to infection (Lind 
et al., 2016), and to study changes in the host immune system during infection (Lincez 
et al., 2015). 
To evaluate the usefulness of the 2Apro and 3C pro antibodies in flow cytometry, HeLa 
cells were infected with CVB3 for 6 h. The cells were then fixed, permeabilized and 
stained with antibodies prior to flow cytometry analysis. The 2A-2 and 3C antibodies, 
as well as the VP1 clone 5-D8/1 antibody, positively stained infected cells and were 
detected by flow cytometry (Figure 3 A). 
Next, double staining was performed in cells infected with CVB3 by combining one of 
the protease antibodies with the VP1 antibody. Flow cytometry analysis revealed 
double positive cells with the majority of VP1 positive cells being co-stained by the 2A 
and 3C antibodies, respectively (Figure 3 B and C).
3.5. 2Apro and 3Cpro mainly localize in the cytoplasm of acutely infected cells
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Advanced microscopy methods, such as confocal microscopy, allow studies examining 
the cellular location of specific proteins. Here, confocal microscopy was employed to 
examine the suitability of the protease antibodies in visualizing the proteases during 
CVB3 infection. HeLa cells were infected by CVB3 for 2, 4 or 6 h and stained with the 
protease antibodies, followed by examination of their intracellular localization over 
time. The protease antibodies stained infected cells but not uninfected control cells. 
Assessment of the expression patterns revealed that 2Apro staining was most intense 
four hours after infection (Figure 4 A and B), whereas the 3Cpro staining was strongest 
at six hours post infection (Figure 4 D and E). A strong staining was seen in the cytosol 
with both protease antibodies, whereas nuclear expression was weak in both cases 
(Figure 4 C and F). 
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4. DISCUSSION
In the present study we introduce three new monoclonal rat antibodies that detect 2Apro 
and 3Cpro proteases in all of the known six CVB serotypes, as well as proteases from 
several other species B EVs. EVs, such as the common CVBs, cause pathologies and 
in this process, the functional proteins (e.g. the proteases), rather than the viral genome 
or the capsid proteins may elicit most of the damage (Badorff et al., 2000; Barnabei et 
al., 2015; Lim et al., 2013; Luo et al., 2010; Massilamany et al., 2014; Wong et al., 
2012). In this respect, the 2Apro and 3Cpro proteases are a pernicious twosome, as they 
are responsible for shutting down many vital cellular functions (Laitinen et al., 2016; 
Lamphear et al., 1993; Weidman et al., 2001), inhibiting the host’s immune response 
to the virus (Feng et al., 2014; Lei et al., 2013; Lind et al., 2016, 2014, 2013; Mukherjee 
et al., 2011) and causing pathogenic changes in certain cell types and tissues (Badorff 
et al., 2000; Barnabei et al., 2015; Lim et al., 2013; Luo et al., 2010; Massilamany et 
al., 2014; Wong et al., 2012). There has been a lack of tools to study 2Apro and 3Cpro
and methods to examine their presence and involvement in cellular processes are likely 
to further enhance our understanding of the mechanisms through which the CVBs cause 
pathology. Such information may open possibilities for the development of therapeutics 
to use in viral diseases.
One of the strengths of the new protease antibodies presented here is their usefulness 
in numerous applications including Western blot, flow cytometry, ICC and IHC. A 
single monoclonal antibody detecting 3Cpro (3C) was compatible with all of the 
methods tested. In contrast, the two 2Apro antibodies showed differences in their 
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usefulness in the various methodologies. While both the 2A-1 and the 2A-2 antibodies 
were functional in Western blot, only 2A-2 successfully detected virus in formalin fixed 
pancreas from infected mice. Moreover, the 2A-2 antibody also worked in ICC, 
confocal microscopy and intracellular flow cytometry. 
Besides their suitability to detect the homotypic virus, CVB3, in various techniques, 
the protease antibodies recognized the other five CVB serotypes. Through IHC analysis 
of cells infected with a selection of other EV species, we found that the antibodies were 
capable of detecting some echoviruses and CVA9. We also compared the ability of the 
2Apro and 3Cpro antibodies to detect EVs in ICC with the VP1 antibody clone 5-D8/1, 
which detects EV species A and some EV species C viruses (namely poliovirus) (Laiho 
et al., 2015). Our results suggest that the protease antibodies are more EV species-
specific than the VP1 antibody. This notion is also supported by phylogenetic analyses 
of VP1, 2Apro and 3Cpro (Supplementary Figures 1-3), in which the proteases sequences 
recognized by 2A-2 and 3C are clustered tightly, whereas the VP1 sequence detected 
by 5-D8/1 is distributed over several clades. The antigen binding site of the VP1 
antibody produced by clone 5-D8/1 has been shown to locate close to the N-terminus 
of VP1 (Samuelson et al., 1995), and is known to be well conserved between EVs 
(Maccari et al., 2016), thereby explaining its broader recognition profile. 
EV-Bs, including the CVBs, are prone to recombination and both inter- and intra-
serotypic recombinations have been described (Oberste et al., 2004a, 2004b). Such 
events could alter the amino acid sequences of 2Apro and 3Cpro and thereby 
potentially also modulate the ability of the new antibodies which were raised to 
the prototype virus CVB3 Nancy to detect more recent virus isolates. Additional 
studies are required to investigate the efficacy of the new antibodies to detect a 
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larger number of such recent isolates. We however find that the 2A pro  and 3C pro 
antibodies bind to viruses of all six CVB serotypes and other EV-Bs, some of which 
have been isolated more recently than CVB3 Nancy, including a CVB1 isolate 
from 1998, and echo3 and CVA9 isolated in 1998 and 2005, respectively  
(Supplementary Table 1). Moreover, a comparison of the 2Apro and 3Cpro amino 
acid sequences from different EV-Bs showed a high level of conservation (Laitinen 
et al., 2016). Thus, it is likely that the new antibodies will be able to detect a broad 
range of more recent and currently circulating CVBs. 
In this study, the antibodies produced were made by immunizing rats with recombinant 
2Apro and 3Cpro. During infection, the EV genome is translated into a polyprotein, which 
is cleaved into the structural and nonstructural proteins by 2Apro and 3Cpro. 
Occasionally, our Western blot analyses of CVB infected HeLa cell lysates revealed 
staining of a few bands with a higher molecular weight than those expected for 2Apro
and 3Cpro. These bands correlate with the estimated sizes of parts of the viral 
polyprotein that have not been fully processed (data not shown).  Hence, it is likely that 
the antibodies also detect unprocessed 2Apro and 3Cpro. Such bands were not found in 
the cell lysates of uninfected cells. These bands were also not observed when the 
antibodies were used to detect recombinant 2Apro and 3Cpro, except in the case of the 
dimer band observed for 3Cpro (Figure 1B). The dimeric forms of these proteases have 
also been observed in previous studies as reviewed in (Laitinen et al., 2016).
The VP1 antibody clone 5-D8/1 is an excellent tool for the detection of a broad range 
of EVs. In some applications and/or studies, it may be beneficial to use antibodies that 
recognize a narrower span of EV groups or even single EV serotypes (Ettischer-Schmid 
et al., 2016; Man-Li et al., 2012; Miao et al., 2009; Yagi et al., 1992). With regards to 
21
this, it is interesting to note that the 3C antibody detected all of the EV-B viruses 
examined, and similarly, the 2A-2 antibody detected all except for Echo9, thereby 
indicating that that both antibodies, and particularly 3C, could constitute excellent EV-
B detection tools. Additional screening with these protease antibodies of all known EV-
B viruses and other viruses outside the EV-B serotypes could be performed to guarantee 
that recognition is limited to EV-B viruses. Such screening should also be performed 
to verify the specificity of the antibodies in detecting EV-B viruses in other applications 
including ELISA, IHC, flow cytometry and Western blot. If further validation confirms 
that these protease antibodies are specific for EV species B viruses, then they could be 
utilized to complement current technologies employed in the identification of EVs in 
research and clinical samples (Kramná et al., 2015; Laiho et al., 2016; Luoto et al., 
2016).
Many experimental EV disease models have been developed in the mouse (Fairweather 
et al., 2012; Jaïdane et al., 2009). For IHC studies in mouse tissues, primary monoclonal 
antibodies of rat origin provide an advantage over those generated in mice. If primary 
mouse antibodies are not directly conjugated, their detection requires the use of a 
secondary antibody directed to mouse immunoglobulins and this secondary antibody 
will inevitably bind to endogenous mouse immunoglobulins present in the tissue 
providing high background staining. This is, for example, a challenge faced with the 
VP1 antibody (clone 5-D8/1), which is of mouse origin. In the present study, the VP1 
antibody was directly biotinylated to omit the need for a secondary antibody, thereby 
rendering it compatible for staining mouse tissue. The 2A and 3C antibodies described 
were generated in rat, which bypasses the need for additional modification before use 
in mouse tissue and further to this, the antibodies should also be suitable for use in 
human tissue samples. 
22
In the end of our studies, we also addressed the usefulness of the protease antibodies in 
confocal microscopy and performed a study examining the subcellular localization of 
the proteases during acute CVB3 infection of HeLa cells. It has been previously 
described that the poliovirus 3Cpro precursor 3CD, when expressed as a fusion protein, 
translocates into the nucleus after poliovirus infection or transfection with 2Apro, in a 
2Apro dependent manner (Sharma et al., 2004; Tian et al., 2011). Similarly, HRV16 
3CD nuclear translocation is dependent on 2Apro activity (Walker et al., 2016).  
Interestingly, according to our confocal microscopy results, both proteases appeared in 
the CVB3 infected HeLa cells within four hours after infection (Figures 4 and 5), and 
this timing of protease appearance was also supported by our Western blot data (Figure 
1 C). The proteases mainly reside in the cell cytosol with an even distribution, whereas 
their nuclear localization was only faint or non-existent within the time frame of the 
studies (up to 6h post infection), suggesting that 2Apro does not initiate similar protease 
translocation after CVB3 infection in our cell system. 
On a final note, this study assessed the suitability of the newly developed 2A and 3C 
protease antibodies for use in various applications for the detection of proteases 
expressed in acute infection models. In future studies, it would be relevant to also assess 
if the antibodies are capable of detecting persistent EV infections, which have been 
shown to develop in the human heart muscle (Gaaloul et al., 2014; Luo et al., 2010). If 
the proteases were also expressed during persistent infections, this would suggest that 
the proteases might contribute to cell and tissue damage sustained during situations of 
viral persistence. 
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In conclusion, we describe three new antibodies that can detect the EV-B species 
proteases 2Apro and 3Cpro and present a number of applications, in which they can be 
used. The antibodies described allow for the cross-validation of other methods and 
antibodies used to detect acute EV infections. Furthermore, the antibodies are suitable 
for use in studies examining the kinetics of infection, the subcellular localization of the 
proteases and may also be used to identify novel mechanisms by which the proteases 
contribute to tissue pathology. Such information can be used for the development of 
new antiviral therapies aimed at blocking virus replication and preventing tissue 
damage. 
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FIGURE LEGENDS
Figure 1. 2A-1 and 3C antibodies detect CVB proteases by Western blot. 
(A,B) HeLa cells were infected with CVB3 (MOI 20). After 6 hours, infected cells were 
lysed and the proteases were detected by SDS-PAGE (15 µg of cell lysate in each well) 
and Western blot using the 2A-1 (A) and 3C (B) antibodies. Purified, recombinant 2Apro 
and 3Cpro (1 µg) were used as positive controls. The band with an approximate size of 
~50 kDa likely represents 3Cpro dimers (B). (C) HeLa cells were infected with CVB3 
(MOI 20) and cultured for the indicated time periods, followed lysis and analysis by 
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SDS-PAGE (15 µg of cell lysate) and Western blot using the 2A-1 and 3C antibodies. 
D) HeLa cells infected with CVB1-6 (MOI 20) were lysed six hours post infection and
proteases as well as VP1 were detected by SDS-PAGE (15 µg of cell lysate) and 
Western blot using antibodies 2A-I, 3C and VP1 antibody clone 5-D8/1. Beta actin was 
used as loading control (A-D).
Figure 2. 2Apro and 3Cpro antibodies detect CVBs in murine tissue.
NOD (panels A-C and E-H) or C57BL/6J (panel D) mice were infected with CVB3 (B, 
D) or CVB5 (F, H) for 5 and 3 days, respectively. Uninfected control mice (A, C, E,
and G) received buffer alone or remained untreated. Pancreases were removed, 
formalin fixed, sectioned and subjected to immunohistochemical staining using 
antibodies 2A-2, 3C or VP1 antibody 5-D8/1, as described in the materials and 
methods. E and G, and F and H, are consecutive tissue sections from the same tissue 
blocks. On representative tissue section per condition is shown, n = 1 - 2 mice per 
condition. The image magnification is 10X for A, B, 5X for C, D and 40X for E-H. 
Figure 3. 2Apro and 3Cpro antibodies identify infected cells by intracellular staining 
and flow cytometry. HeLa cells were infected with CVB3 (MOI 20) for 6h, after which 
they were fixed and permeabilized prior to intracellular staining with primary 2Apro or 
3Cpro antibodies. Primary antibodies were detected using a Phycoerythrin (PE) labeled 
secondary antibody (2Apro and 3Cpro) and goat anti-mouse Alexa Fluor 647- (A) or 
Alexa Fluor 488-conjugated (B-C) secondary antibodies (VP1). Infection was 
confirmed by VP1 staining. One representative experiment out of n = 1 - 3 per condition 
is shown. 
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Figure 4. Confocal microscopy shows a time dependent appearance of 2Apro and 
3Cpro in the cytosol of CVB3 infected HeLa cells. HeLa-cells were infected with 
CVB3 (MOI 20) for 2, 4 and 6 h and stained for 2Apro or 3Cpro, nuclear lamin and 
nuclear DNA. A) CVB3 infected HeLa cells stained for nuclear DNA (DAPI; blue), 
nuclear lamina (red) and 2Apro (green). B) HeLa cells infected with CVB3 stained for 
2Apro (black). C) Intensity profile of CVB3 infected HeLa-cells for lamin (red) and 
2Apro (green) antibodies at four hours post infection. This analysis was performed on 
the cell indicated by the white box in panel A. D) CVB3 infected HeLa-cells stained 
for nuclear DNA (DAPI; blue), nuclear lamina (red) and 3Cpro (green). E) HeLa-cells 
infected with CVB3 stained for 3Cpro (black). F) Intensity profile of CVB3 infected 
HeLa-cell for lamin (red) and 3Cpro (green) at six hour post infection. This analysis was 
performed on the cell indicated by white box in panel D. These figures are 
representative out of three separate experiments.
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Table 1. Detection of enteroviruses by the new 2Apro and 3Cpro antibodies using immunocytochemistry and a comparison to the detection by the VP1 antibody clone 5-D8/1.
Cell line Virus species Serotype 2A-2a 3Cb VP1c
GMK - Uninfected - - -
GMK EV B CVA9 + + +
GMK EV B CVB1 + + +
GMK EV B CVB2 + + +
GMK EV B CVB3 + + +
GMK EV B CVB4 + + +
GMK EV B CVB5 + + +
GMK EV B CVB6 + + +
GMK EV B Echo3 N/A + +
GMK EV B Echo4 + + +
GMK EV B Echo6 + + +
GMK EV B Echo9 - + +
GMK EV B Echo11 + + +
GMK EV A EV71 - - -
GMK EV C PV3 - - +
A549 - Uninfected - - -
A549 EV B Echo30 + + +
A549 HPev HPev1 - - -
RD - Uninfected - - -
RD EV A CVA2 - - +
RD EV A CVA4 - - +
RD EV A CVA5 - - +
36
RD EV A CVA6 - - +
RD EV B CVA9 - + +
RD EV A CVA10 - - +
RD EV A CVA16 - - +
HeLa - Uninfected - - -
HeLa Adeno Adeno C - - -
Vero - Uninfected - - -
Vero EV A CVA16 - - -
aAntigen retrieval: 10mM citrate, pH6
bAntigen retrieval: 10mM Tris 1mM EDTA, pH9
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Supplementary Materials and Methods
Phylogenetic analyses
Example sequences for each virus were fetched from the NCBI database and they were 
aligned with ClustalX (Larkin et al., 2007). The phylogenetic trees were generated with 
Mega 6 (Tamura et al., 2013). In each case, HPeV1 was manually set as the outgroup.
2The detailed information about viruses used in the study
Supplementary table 1. Used viruses and their originVirus species Serotype Virus strain/origin Used MethodsEV B CVA9 ATCC CMAEV B CVB1 ATCC CMACVB1 CDC11 was isolated in Argentina at year 19981 WBEV B CVB2 ATCC CMA, WBEV B CVB3 ATCC Nancy CMA, WB, IHC, FC, CMEV B CVB4 ATCC CMACVB4 E22 WBEV B CVB5 ATCC CMA, WB, IHCEV B CVB6 ATCC CMA, WBEV B Echo3 PB-E3DiT23 isolated in Finland 19983 CMAEV B Echo4 ATCC CMAEV B Echo6 ATCC CMAEV B Echo9 ATCC CMAEV B Echo11 ATCC CMAEV A EV71 PB-EV71Hus CMAEV C PV3 Sabin CMAEV B Echo30 ATCC CMAHPev HPev1 ATCC Strain Harris CMAEV A CVA2 PB-CVA2V38/Close resemblance to Coxsackievirus A2 isolate EV_NL_94 VP1 gene4 CMAEV A CVA4 PB-CVA4V36/Close resemblance to CVA4 isolate 10433, 2005 according to5 CMAEV A CVA5 PB-CVA5V43/ Close resemblance to isolate P-550/CA5/Kanagawa/20005 CMAEV A CVA6 PB-CVA6V303V/Close resemblance to isolate CSF-1739/07 VP15 CMAEV B CVA9 PB-CVA9V59/Close resemblance to FR-08-2005-1495 CMAEV A CVA10 PB-CVA10V2530/Close resemblance toP-2206/CA10/Kanagawa/20035 CMAEV A CVA16 PB-CVA16V55/ Close resemblance to W42-44/015 CMAAdeno Adeno C VR 846 CMAEV A CVA16 ATCC CMACMA, cell microarray; EV, enterovirus; CVA, Coxsackievirus A; CVB, Coxsackievirus B; IHC, immunohistochemistry; WB, Western Blot; FC, Flow cytometry; CM, Confocal microscopy1(Hämäläinen et al., 2014); 2(Kang et al., 1994); 3(Laiho et al., 2015); 4Laitinen et al. unpublished; 5(Laitinen et al., 2014)
3Supplementary results
Sequence alignments of proteases and VP1 support the antibody detection 
pattern observed with the experimental methods
In order to see how the proteases from the different viruses that were detected in the 
cell array by immunocytochemistry cluster, an example protein sequence for 2Apro, 
3Cpro and VP1 were aligned and phylogenetic trees were generated for both proteases 
and VP1 separately (Supplementary Figures 1-3). This analysis indicated that virus 
strains are phylogenetically clustered at the antibody recognition patterns, further 
supporting the idea of epitope variation between virus species. 
4Supplementary Figure 1. Phylogenetic analysis of the 2Apro part of the viruses used 
in the study. Viral proteases recognized by the 2A-2 antibody in immunocytochemical 
analysis are highlighted with orange color. The CVA9 2Apro recognized in infected 
GMK cells but not in RD cells is marked with light green.
5Supplementary Figure 2. Phylogenetic analysis of the 3Cpro part of the viruses used 
in the study. Viral proteases recognized by the 3C antibody in immunocytochemical 
analysis are highlighted with orange.
6Supplementary Figure 3. Phylogenetic analysis of the VP1 part of the viruses used 
in the study. Viral proteases recognized by the anti-VP1 clone 5-D8/1 antibody in 
immunocytochemical analysis are highlighted with orange color.
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